ESC 2018 SGLT2 inhibitors CV mortality type 2 diabetes

Content for healthcare professionals only

View all Platforms Cardiology

Topics Content Type Videos Articles Journals Broadcasts Education Podcasts News Journals AER CFR ECR ICR3 JAPSC USC Faculty Events Upcoming Events Radcliffe Events All Events Resource Hubs Deep Vein Thrombosis Empagliflozin in the Treatment of Chronic Heart Failure Pulmonary Embolism Pulsed Field Ablation

Radcliffe Platforms

Radcliffe Group Cardiology Vascular CVRM Medical Education

Content for healthcare professionals only

Topics

Content Type

Journals

Faculty

Events

Resource Hubs

Video

ESC 2018: Use of SGLT2 inhibitors in clinical practice to reduce CV mortality in patients with type 2 diabetes

Published: 22 Oct 2018

Views:
546
Likes:
0

Average (ratings)

No ratings

Your rating

Esc 2018: Use of sglt2 Inhibitors in Clinical Practice to Reduce CV Mortality in Patients With Type 2 Diabetes - Prof Javed Butler & Prof Stefan Anker

Filmed on-site at ESC 2018 by Radcliffe Cardiology.